CLDX
HEALTHCARECelldex Therapeutics Inc
$34.39+0.53 (+1.57%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CLDX Today?
No stock-specific AI insight has been generated for CLDX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$18.20$35.79
$34.39
Fundamentals
Market Cap$2.7B
P/E Ratio—
EPS$-3.90
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume535K
Avg Volume (10D)—
Shares Outstanding78.5M
CLDX News
20 articles- Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Celldex Reports First Quarter Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Innoviva (INVA) Tops Q1 Earnings EstimatesYahoo Finance·May 7, 2026
- Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?Yahoo Finance·May 4, 2026
- Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price JumpYahoo Finance·Apr 25, 2026
- Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast EnrollmentMarketbeat·Apr 15, 2026
- Celldex to Present at Upcoming Investor ConferenceYahoo Finance·Apr 13, 2026
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire Inc.·Apr 6, 2026
- Celldex shares plunge after dumping $300 million stock dealYahoo Finance·Apr 2, 2026
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Escalation Signals in Iran Conflict Lift Oil PricesYahoo Finance·Apr 2, 2026
- Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX?Yahoo Finance·Apr 2, 2026
- Celldex Announces Pricing of $300 Million Public Offering of Common StockGlobeNewswire Inc.·Apr 2, 2026
- Celldex Announces Proposed Public Offering of Common StockYahoo Finance·Apr 1, 2026
- Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026Yahoo Finance·Mar 27, 2026
- High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest HoldingMotley Fool·Mar 21, 2026
- A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness And Strong 1 Year ReturnYahoo Finance·Mar 19, 2026
- Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data CatalystsMarketbeat·Mar 14, 2026
- Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen ConferenceMarketbeat·Mar 8, 2026
- Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026Yahoo Finance·Mar 1, 2026
- Celldex Therapeutics, Inc. (CLDX): A Bull Case TheoryYahoo Finance·Feb 28, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$33.86
Day High$0.00
Day Low$0.00
52 Week High$35.79
52 Week Low$18.20
52-Week Range
$18.20$35.79
$34.39
Fundamentals
Market Cap$2.7B
P/E Ratio—
EPS$-3.90
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume535K
Avg Volume (10D)—
Shares Outstanding78.5M
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—